DJIA 18,214.42 -10.15 -0.06%
NASDAQ 4,987.89 20.75 0.42%
S&P 500 2,110.74 -3.12 -0.15%
market minute promo

Nektar Therapeutics (NASDAQ: NKTR)



company name or ticker

Nektar Therapeutics' (NKTR) CEO Howard Robin on Q2 2014 Results - Earnings Call Transcript

Nektar: Reason Will Rarely Fail You

Nektar Therapeutics (NKTR): New Analyst Report from Zacks Equity Research - Zacks Equity Research Re

Nektar Therapeutics (NKTR): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

Can Anything Derail Salix Pharmaceuticals?

Expanded labeling for the sub-q form of Relistor could add $100 million in revenue, but doesn't change the business to a large extent

Why GW Pharmaceuticals Could be the Next Marijuana Bubble Stock to Pop

Shares of GW Pharmaceuticals have more than doubled in the last year.

AstraZeneca's Naloxegol Data Published - Analyst Blog

Regado Biosciences: The Revolyxis Revolution Has Begun

Nektar Therapeutics (NKTR) in Focus: Stock Rises 10.77% - Tale of the Tape

A Nektar Victory

This Week in Biotech: Actions Speak Louder Than Words

Regulatory actions provided the impetus to big moves for these five biotech stocks.
See More Articles...